Intellia Therapeutics (NTLA) Misses Q2 EPS by 38c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Intellia Therapeutics (NTLA) Misses Q2 EPS by 38c

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 5, 2021 7:30 AM EDT

Established proof of concept for the Companys modular in vivo delivery platform with first-ever clinical data from systemically administered CRISPR genome editing candidate in humansInterim Phase 1 data from first two cohorts show NTLA-2001 was well-tolerated and achieved deep TTR reduction, with a maximum 96% serum TTR reduction by day 28, demonstrating potential as single-dose treatment for transthyretin (ATTR) amyloidosis; plan to report additional data from ongoing study this year Plans to initiate first-in-human studies for both NTLA-2002 for hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia (AML) this yearLaunched CAR... More